Chinese Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Registry protocol : rationale, design and methodology
© 2024. The Author(s)..
BACKGROUND: Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS.
METHOD: Thirty Chinese cardiovascular centers have collaborated to create a multicenter observational registry (named Chinese Additive Anti-inflammatory Action for Aortopathy & Arteriopathy [5A] registry), with consecutive enrollment of adult patients who underwent surgery for AAS that was started on Jan 1, 2016 and will be ended on December 31, 2040. Specially, the impact of inflammation and anti-inflammatory strategies on the early and late adverse events are investigated. Primary outcomes are severe systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), Sequential Organ Failure Assessment (SOFA) scores at 7 days following this current surgery. Secondary outcomes are SISR, 30-day mortality, operative mortality, hospital mortality, new-onset stroke, acute kidney injury, surgical site infection, reoperation for bleeding, blood transfusion and length of stay in the intensive care unit.
DISCUSSION: The analysis of this multicenter registry will allow our better knowledge of the prognostic importance of preoperative inflammation and different anti-inflammatory strategies in adverse events after surgery for AAS. This registry is expected to provide insights into novel different inflammatory resolutions in management of AAS beyond conventional surgical repair.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04398992 (Initial Release: 05/19/2020).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC cardiovascular disorders - 24(2024), 1 vom: 21. Feb., Seite 120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Hong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute aortic syndrome |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 06.03.2024 published: Electronic ClinicalTrials.gov: NCT04398992 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12872-024-03760-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36873336X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36873336X | ||
| 003 | DE-627 | ||
| 005 | 20240307232409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12872-024-03760-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM36873336X | ||
| 035 | |a (NLM)38383323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Hong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chinese Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Registry protocol |b rationale, design and methodology |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04398992 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS | ||
| 520 | |a METHOD: Thirty Chinese cardiovascular centers have collaborated to create a multicenter observational registry (named Chinese Additive Anti-inflammatory Action for Aortopathy & Arteriopathy [5A] registry), with consecutive enrollment of adult patients who underwent surgery for AAS that was started on Jan 1, 2016 and will be ended on December 31, 2040. Specially, the impact of inflammation and anti-inflammatory strategies on the early and late adverse events are investigated. Primary outcomes are severe systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), Sequential Organ Failure Assessment (SOFA) scores at 7 days following this current surgery. Secondary outcomes are SISR, 30-day mortality, operative mortality, hospital mortality, new-onset stroke, acute kidney injury, surgical site infection, reoperation for bleeding, blood transfusion and length of stay in the intensive care unit | ||
| 520 | |a DISCUSSION: The analysis of this multicenter registry will allow our better knowledge of the prognostic importance of preoperative inflammation and different anti-inflammatory strategies in adverse events after surgery for AAS. This registry is expected to provide insights into novel different inflammatory resolutions in management of AAS beyond conventional surgical repair | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04398992 (Initial Release: 05/19/2020) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute aortic syndrome | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Systemic inflammatory response syndrome | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 700 | 1 | |a Qian, Si-Chong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hai-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Yong-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hong-Jia |e verfasserin |4 aut | |
| 700 | 0 | |a China Additive Anti-inflammatory Action for Aortopathy, Arteriopathy (5A) Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hong |e investigator |4 oth | |
| 700 | 1 | |a Qian, Si-Chong |e investigator |4 oth | |
| 700 | 1 | |a Li, Hai-Yang |e investigator |4 oth | |
| 700 | 1 | |a Han, Lu |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Ying-Yuan |e investigator |4 oth | |
| 700 | 1 | |a Wang, Kai |e investigator |4 oth | |
| 700 | 1 | |a Wu, Ying |e investigator |4 oth | |
| 700 | 1 | |a Hong, Liang |e investigator |4 oth | |
| 700 | 1 | |a Yang, Ji-Nong |e investigator |4 oth | |
| 700 | 1 | |a Zhong, Ji-Sheng |e investigator |4 oth | |
| 700 | 1 | |a Sun, Bing-Qi |e investigator |4 oth | |
| 700 | 1 | |a Liu, Xiao-Cheng |e investigator |4 oth | |
| 700 | 1 | |a Wu, Dong-Kai |e investigator |4 oth | |
| 700 | 1 | |a Fan, Guo-Liang |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jun-Quan |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Sheng-Qiang |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Yi-Yao |e investigator |4 oth | |
| 700 | 1 | |a Peng, Xing-Xing |e investigator |4 oth | |
| 700 | 1 | |a Zeng, Zhi-Hua |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Xin |e investigator |4 oth | |
| 700 | 1 | |a Tang, Peng-Cheng |e investigator |4 oth | |
| 700 | 1 | |a Feng, Xiao-Yan |e investigator |4 oth | |
| 700 | 1 | |a Tang, Cheng-Bin |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Hui-Jun |e investigator |4 oth | |
| 700 | 1 | |a Lu, Zhan-Jie |e investigator |4 oth | |
| 700 | 1 | |a Zheng, Si-Qiang |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Chen |e investigator |4 oth | |
| 700 | 1 | |a Shao, Yong-Feng |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Hong-Jia |e investigator |4 oth | |
| 700 | 1 | |a Zhu, Peng-Cheng |e investigator |4 oth | |
| 700 | 1 | |a Yue, Hong-Hua |e investigator |4 oth | |
| 700 | 1 | |a Huang, Ling-Chen |e investigator |4 oth | |
| 700 | 1 | |a Wu, Feng |e investigator |4 oth | |
| 700 | 1 | |a Xu, Xiao-Han |e investigator |4 oth | |
| 700 | 1 | |a Lu, Xiao-Hu |e investigator |4 oth | |
| 700 | 1 | |a Gu, Wei-Dong |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cardiovascular disorders |d 2001 |g 24(2024), 1 vom: 21. Feb., Seite 120 |w (DE-627)NLM11347802X |x 1471-2261 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:21 |g month:02 |g pages:120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12872-024-03760-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 21 |c 02 |h 120 | ||